These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35257864)

  • 1. Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: A cross-sectional analysis.
    Lucasson F; Balanescu A; Kiltz U; Leung YY; Aydin SZ; Gaydukova I; Lubrano E; Coates LC; de Wit M; Orbai AM; Gossec L
    Joint Bone Spine; 2022 Oct; 89(5):105372. PubMed ID: 35257864
    [No Abstract]   [Full Text] [Related]  

  • 2. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
    Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
    RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
    Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
    J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors in psoriatic arthritis].
    Fernández Sueiro JL; Lema Gontad JM
    Reumatol Clin; 2012 Mar; 8 Suppl 1():S7-9. PubMed ID: 22257679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic arthritis: is it time to treat-to-target or target to treat?
    Lubrano E; Perrotta FM
    Clin Rheumatol; 2017 Dec; 36(12):2633-2635. PubMed ID: 29067586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?
    Mulder MLM; den Broeder AA; van Ginneken BTJ; Mahler EAM; van den Hoogen FHJ; Vriezekolk JE; Wenink MH
    Rheumatology (Oxford); 2019 Dec; 58(12):2330-2331. PubMed ID: 31230083
    [No Abstract]   [Full Text] [Related]  

  • 9. Remission criteria and activity indices in psoriatic arthritis.
    Acosta Felquer ML; Ferreyra Garrott L; Marin J; Catay E; Scolnik M; Scaglioni V; Ruta S; Rosa J; Soriano ER
    Clin Rheumatol; 2014 Sep; 33(9):1323-30. PubMed ID: 24820142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
    Haugeberg G; Michelsen B; Kavanaugh A
    RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treat-to-target in PsA: methods and necessity.
    Dures E; Shepperd S; Mukherjee S; Robson J; Vlaev I; Walsh N; Coates LC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32071281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment in psoriatic arthritis.
    Salvarani C; Pipitone N; Catanoso MG
    Reumatismo; 2007; 59 Suppl 1():68-72. PubMed ID: 17828349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early psoriatic arthritis.
    Gladman DD
    Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.
    Soriano ER; Zazzetti F; Alves Pereira I; Maldonado Cocco J; Feijó Azevedo V; Guerra G; Bautista-Molano W; Casasola JC; Vega Morales D; Gil DR; Lobosco S; Lawson F
    Clin Rheumatol; 2020 Jun; 39(6):1859-1869. PubMed ID: 31993888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Comorbidities and Quality of Life in Psoriatic Arthritis: Results from a Multicentric Cross-sectional Study.
    Bavière W; Deprez X; Houvenagel E; Philippe P; Deken V; Flipo RM; Paccou J
    J Rheumatol; 2020 Mar; 47(3):369-376. PubMed ID: 31203223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.
    Coates LC; Rahman P; Psaradellis E; Rampakakis E; Osborne B; Lehman AJ; Nantel F
    Rheumatology (Oxford); 2019 Mar; 58(3):522-526. PubMed ID: 30517715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment recommendations for psoriatic arthritis].
    Boehncke WH
    Z Rheumatol; 2009 Dec; 68(10):842-4. PubMed ID: 19937037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.